Halting angiogenesis suppresses carcinoma cell invasion

Nature Medicine

Volumn 3, Issue 11, 1997, Pages 1222-1227

  Skobe, Mihaela ^a,c   Rockwell, Patricia ^b   Goldstein, Neil ^b   Vosseler, Silvia ^a   Fusenig, Norbert E ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CARCINOMA; CELL PROLIFERATION; IN SITU HYBRIDIZATION; KERATINOCYTE; PRIORITY JOURNAL;

MUS MUSCULUS;

EID: 0030701960     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1197-1222     Document Type: Article

References (40)

1. Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
2. Gimbrone, M., Leapman, S., Cotran, R. & Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276 (1972).
3. Nicosia, R.F., Tchao, R. & Leighton, J. Interaction between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin. Exp. Metastasis 4, 91-104 (1986).
4. Hamada, J., Cavanaugh, P.G., Lotan, O. & Nicolson, G. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br. J. Cancer 66, 349-354 (1992).
5. Rak, J.W., Filmus, J. & Kerbel, R.S. Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis. Eur. J. Cancer 32A, 2438-2450 (1996).
6. Weidner, N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9-15 (1995).
7. Liotta, L., Kleinerman, J. & Saidel, F. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34, 997-1004 (1974).
8. Larcher, F. et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 56, 5391-5396 (1996).
9. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
10. Christofori, C. & Hanahan, D. Molecular dissection of multistage tumorigenesis in transgenic mice. Semin. Cancer Biol. 5, 3-21 (1994).
11. Brooks, P.C. et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 (1995).
12. Ferrara, N. & Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858 (1989).
13. Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039 (1995).
14. Alon, T. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1, 1024-1028 (1995).
15. Terman, B.I. & Dougher-Vermazen, M. Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev. 15, 159-163 (1996).
16. Kim, K.J. et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
17. Cheng, S.-Y. et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U S A 93, 8502-8507 (1996).
18. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 367, 576-579 (1994).
19. Millauer, B. et al. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620 (1996).
20. Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A. & Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789-1797 (1995).
21. Ferrara, N. et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J. Clin. Invest. 91, 160-170 (1993).
22. Zhang, H.-T. et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst. 87, 213-219 (1995).
23. Claffey, K.P. et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis. Cancer Res. 56, 172-181 (1996).
24. Detmar, M. Molecular regulation of angiogenesis in the skin. J. Invest. Dermatol. 106, 207-208 (1996).
25. Boukamp, P. et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106, 761-771 (1988).
26. Boukamp, P., Stanbridge, E.J., Foo, D.Y., Cerutti, P.A. & Fusenig, N.E. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res. 50, 2840-2847 (1990).
27. H oncogene activation and additional chromosome loss. Oncogene 11, 961-969 (1995).
28. Fusenig, N.E., Breitkreutz, D., Bohnert, A. & Mackenzie, I.C. Epithelial-mesenchymal interactions in tissue homeostasis and malignant transformation. in: Oral Cancer. (ed. Johnson, N.W.) 218-248 (Cambridge Univ. Press, Cambridge, 1991).
29. Breitkreutz, D. et al. Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res. 51, 4402-4409 (1991).
30. Rockwell, P., Neufeld, G., Glassman, A., Caron, D. & Goldstein, N. In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody. Mol. Cell Differ. 3(1), 91-109 (1995).
31. Saez, E. et al. C-fos is required for malignant progression of skin tumors. Cell 82,. 721-732 (1995).
32. Parangi, S. et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007 (1996).
33. Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969 (1997).
34. Mandriota, S.J., Menoud, A.-P. & Pepper, M.S. Transforming growth factor β1 downregulates vascular endothelial growth factor receptor 2/flk-1 in vascular endothelial cells. J. Biol. Chem. 271, 11500-11505 (1996).
35. Patterson, C. et al. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor a in cultured human vascular endothelial cells. J. Clin. Invest. 98, 490-496 (1996).
36. Yoshida, A., Anandapte, B. & Zetter, B.R. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13, 57-64 (1996).
37. Holmgren, L., O'Reilly, M.S. & Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153 (1995).
38. Tischer, E. et al. The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954 (1991).
39. Millauer, B. et al. High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846 (1993).
40. Moorman, A.F.M., De-Boer, P.A.J., Vermeulen, J.L.M. & Lamers, W.H. Practical aspects of radio-isotopic in situ hybridization on RNA. Histochem. J. 25, 251-266 (1992).